...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neurologia medico-chirurgica. >Adverse Effects of Intravenous Acetazolamide Administration for Evaluation of Cerebrovascular Reactivity Using Brain Perfusion Single-Photon Emission Computed Tomography in Patients With Major Cerebral Artery Steno-occlusive Diseases.
【24h】

Adverse Effects of Intravenous Acetazolamide Administration for Evaluation of Cerebrovascular Reactivity Using Brain Perfusion Single-Photon Emission Computed Tomography in Patients With Major Cerebral Artery Steno-occlusive Diseases.

机译：使用脑灌注单光子发射计算机断层扫描术对主要脑动脉狭窄闭塞性疾病患者进行静脉给予乙酰唑胺评估对脑血管反应性的不良影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography (SPECT) were prospectively investigated in 100 patients with major cerebral artery, atherosclerotic, and steno-occlusive diseases. All patients underwent two SPECT studies (with and without acetazolamide challenge) at an interval of 2 or 3 days, received a questionnaire immediately after each SPECT study, and returned the answered questionnaire within 7 days after the study. None of the 100 patients studied experienced any symptoms during the SPECT study without acetazolamide challenge. Sixty-three patients (63%) developed symptoms during the SPECT study with acetazolamide challenge, such as headache, nausea, dizziness, tinnitus, numbness of the extremities, motor weakness of the extremities, and general malaise 1-3 hours (mean 1.6 hours) after administration of acetazolamide, and these symptoms lasted for 0.5-72 hours (mean 7.9 hours). Multivariate statistical analysis revealed that younger age (95% confidence interval [CI] 0.896-0.980, p = 0.0047) and female sex (95% CI 1.178-16.129, p = 0.0274) were significantly associated with development of symptoms with acetazolamide challenge. The incidences of the development of symptoms with acetazolamide challenge were 91% (21/23) and 41% (12/29) in subgroups of women <70 years and men >/=70 years, respectively. Patients should be informed of such adverse effects of intravenous acetazolamide administration prior to the acetazolamide challenge test for evaluation of cerebrovascular reactivity.
机译：前瞻性地调查了100名患有主要脑动脉，动脉粥样硬化和狭窄闭塞性疾病的患者，使用脑灌注单光子发射计算机断层扫描（SPECT）评估了静脉给予乙酰唑胺对评估脑血管反应性的不良影响。所有患者每隔2或3天进行两次SPECT研究（有或没有乙酰唑胺激发），每次SPECT研究后立即接受调查表，并在研究后7天内返回回答的调查表。没有乙酰唑胺攻击的情况下，在100名接受研究的患者中，没有任何患者出现任何症状。 63位患者（63％）在接受SPECT研究期间出现乙酰唑胺攻击症状，例如头痛，恶心，头晕，耳鸣，肢体麻木，肢体运动无力和全身不适1-3小时（平均1.6小时） ）在服用乙酰唑胺后，这些症状持续了0.5-72小时（平均7.9小时）。多变量统计分析表明，年龄较小（95％置信区间[CI] 0.896-0.980，p = 0.0047）和女性（95％CI 1.178-16.129，p = 0.0274）与乙酰唑胺激发的症状发展密切相关。在70岁以下的女性亚组和70岁以上的男性亚组中，乙酰唑胺攻击症状发展的发生率分别为91％（21/23）和41％（12/29）。在进行乙酰唑胺激发试验以评估脑血管反应性之前，应告知患者静脉给予乙酰唑胺的此类不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号